Comparative Pharmacology
Head-to-head clinical analysis: ENBUMYST versus MUCOSIL 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBUMYST versus MUCOSIL 10.
ENBUMYST vs MUCOSIL-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetylcysteine reduces mucus viscosity by cleaving disulfide bonds in mucoproteins, facilitating airway clearance. It also restores glutathione levels in acetaminophen toxicity.
MUCOSIL-10 is a mucolytic agent containing N-acetylcysteine. It reduces mucus viscosity by cleaving disulfide bonds in mucoproteins via free sulfhydryl groups, thereby facilitating expectoration. It also exhibits antioxidant properties by replenishing glutathione stores and neutralizing reactive oxygen species.
600 mg orally twice daily (total daily dose 1200 mg) for 12 weeks in combination with other anti-TB drugs.
10 mg orally once daily
None Documented
None Documented
Terminal half-life: 6-8 hours in healthy adults; prolonged in hepatic impairment (up to 12 hours) and severe renal impairment (up to 10 hours).
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; may be prolonged to 6-8 hours in patients with moderate renal impairment (CrCl <50 mL/min).
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Primarily renal elimination with 60-70% of the dose excreted unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites, with the remainder via other pathways.
Category C
Category C
Mucolytic
Mucolytic